Category: Cardiology
-
How digital twins are pioneering a new era of personalized, longitudinal healthcare
Dr. Amanda Randles explains how they are developing digital twins to move medicine beyond static snapshots to dynamic, personalized care.
-
2025 in Review: Global biotech and funding trends
Deepali Suri, President of ICON Biotech, discusses Asia’s clinical trial boom, funding shifts, and why neurology and cardiology are surpassing oncology.
-
Stereotaxis MAGiC catheter cleared by FDA for robotic heart ablation
The US FDA approves Stereotaxis’ robotic magnetic navigation catheter for complex cardiac arrhythmia procedures.
-
Milestone Pharma wins FDA nod for self-administered nasal spray for PSVT
The at-home treatment is designed to manage acute symptomatic episodes outside of emergency healthcare settings.
-
HeartBeam’s stock shows strong pulse after FDA clearance
A cable-free, credit-card sized ECG device for at-home heart monitoring receives regulatory approval, paving the way for a 2026 launch.
-
Pharvaris stock rises following positive Phase III topline data
The company’s oral drug deucrictibant significantly sped up symptom relief in the Phase III trial, positioning it for 2026 regulatory filings.
-
Levron Medical emerges with new approach to treating heart failure
Following first-in-human results and new funding, the company prepares for a clinical study at Sheba Medical Center.
-
AHA 2025: Amgen’s Repatha cuts first heart event risk by 25%
Landmark trial shows Repatha significantly reduces major cardiovascular events in high-risk patients without prior heart attack or stroke.
-
CorVista’s test shows promise for early pulmonary hypertension diagnosis
The newly published case series highlights CorVista System’s ability to detect pulmonary hypertension earlier than traditional methods.
-
Stereotaxis boasts completion of first US robotic HD mapping procedure
Deborah Heart and Lung Center pioneers first US use of Stereotaxis’ MAGiC Sweep catheter for robotic arrhythmia mapping.
-
Merck’s oral PCSK9 inhibitor finds another Phase III success
The pivotal CORALreef Lipids trial assessing enlicitide in hypercholesterolemia patients met all primary and key secondary endpoints.
-
Novartis sharpens focus on cardiovascular innovation at ESC 2025
Novartis exec, Dr Glaser, highlights Leqvio, pelacarsen, abelacimab, and Entresto in new data advancing cardiovascular care.
Latest posts
-
How digital twins are pioneering a new era of personalized, longitudinal healthcare
Dr. Amanda Randles explains how they are developing digital twins to move medicine beyond static snapshots to dynamic, personalized care.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
From data to desire: How Pharma learned to win the Super Bowl
Pharma marketing exec on how health brands are trading clinical claims for cultural currency—and what the FDA’s latest warning means for the future.
-
How LSD and classic psychedelics are re-entering modern psychiatry
Definium’s CMO talks about evaluating psychedelic medicine(s) in the modern era and developing novel treatments for mental health disorders.
-
How human organs are rewriting the rules of drug development
Dr. Jenna DiRito talks about why human organs may represent the “missing chapter” in our understanding of disease, and how this approach is already changing conversations with investors and regulators.